A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. (Q42996520)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

title

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

1 reference

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Brian Edlin

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

Ira M Jacobson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Stevan A Gonzalez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Furqaan Ahmed

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Edward Lebovics

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Albert D Min

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Henry C Bodenheimer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Robert S Brown

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Norbert Bräu

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Franklin M Klion

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Hillel Tobias

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Edmund J Bini

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Neil Brodsky

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Maurice A Cerulli

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Ayse Aytaman

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Peter W Gardner

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Jane M Geders

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Julie E Spivack

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Michael G Rahmin

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

David H Berman

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

James Ehrlich

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Mark W Russo

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Maxwell Chait

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Deborah Rovner

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

language of work or name

English

0 references

publication date

1 November 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

The American Journal of Gastroenterology

9 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

2453-2462

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16279900%20AND%20SRC:MED&resulttype=core&format=json

Therapy of hepatitis C: re-treatment with alpha interferon

9 January 2020

uses

randomized experiment

0 references

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, Franc

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Image of the month. Choledochocele type 3 choledochal cyst.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X

Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00282.X